Intensive Care Medicine

, Volume 31, Issue 5, pp 686–692 | Cite as

Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit

  • Margarita BurmesterEmail author
  • Quen Mok
Pediatric Original



To evaluate and compare the efficacy, infusion rate and recovery profile of vecuronium and cisatracurium continuous infusion in critically ill children requiring mechanical ventilation.

Design and setting

Prospective, randomised, double-blind, single-centre study in critically ill children in a paediatric intensive care unit in a tertiary children’s hospital.


Thirty-seven children from 3 months to 16 years old (median 4.1 year) were randomised to receive either drug; those already receiving more than 6 h of neuromuscular blocking drugs were excluded. The Train-of-Four (TOF) Watch maintained neuromuscular blockade to at least one twitch in the TOF response. Recovery time was measured from cessation of infusion until spontaneous TOF ratio recovery of 70%.


The cisatracurium infusion rate in nineteen children averaged 3.9±1.3 µg kg−1 min−1 with a median duration of 63 h (IQR 23–88). The vecuronium infusion rate in 18 children averaged mean 2.6±1.3 µg kg−1 min−1 with a median duration of 40 h (IQR 27–72). Median time to recovery was significantly shorter with cisatracurium (52 min, 35–73) than with vecuronium (123 min, 80–480). Prolonged recovery of neuromuscular function (>24 h) occurred in one child (6%) on vecuronium.


Recovery of neuromuscular function after discontinuation of neuromuscular blocking drug infusion in children is significantly faster with cisatracurium than vecuronium. Neuromuscular monitoring was not sufficient to eliminate prolonged recovery in children on vecuronium infusions.


Cisatracurium Vecuronium Train-of-Four Mechanical ventilation Paediatric intensive care unit Neuromuscular blockade 



We thank Dr. Angie Wade for statistical help and the PICU nurses for their help in conducting the study.


  1. 1.
    Rudis MI, Guslits BJ, Peterson EL, Hathaway SJ, Angus E, Beis S, Zarowitz BJ (1996) Economic impact of prolonged motor weakness complicating neuromuscular blockade in the intensive care unit. Crit Care Med 24:1749–1756Google Scholar
  2. 2.
    Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD (1992) Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 327:524–528Google Scholar
  3. 3.
    Barnes PK, Renzy-Martin N, Thomas VJ, Watkins J (1986) Plasma histamine levels following atracurium. Anaesthesia 41:821–824Google Scholar
  4. 4.
    Chapple DJ, Miller AA, Ward JB, Wheatley PL (1987) Cardiovascular and neurological effects of laudanosine. Studies in mice and rats, and in conscious and anaesthetized dogs. Br J Anaesth 59:218–225Google Scholar
  5. 5.
    Bion JF, Bowden MI, Chow B, Honisberger L, Weatherley BC (1993) Atracurium infusions in patients with fulminant hepatic failure awaiting liver transplantation. Intensive Care Med 19 [Suppl 8]Google Scholar
  6. 6.
    Manthous CA, Chatila W (1995) Atracurium and status epilepticus? Crit Care Med 23:1440–1442Google Scholar
  7. 7.
    Lepage JY, Malinovsky JM, Malinge M, Lechevalier T, Dupuch C, Cozian A, Pinaud M, Souron R (1996) Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg 83:823–829Google Scholar
  8. 8.
    Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR (1996) Importance of the organ-independent elimination of cisatracurium. Anesth Analg 83:1065–1071Google Scholar
  9. 9.
    Soukup J, Doenicke A, Hoernecke R, Qass J (1997) Cisatracurium-is the stereoisomer an “ideal” relaxant? Histamine liberation and tryptase determination after bolus administration of cistracurium: a comparison with vecuronium. Anaesthesist 46:486–491Google Scholar
  10. 10.
    Prielipp RC, Coursin DB, Scuderi PE, Bowton DL, Ford SR, Cardenas VJ Jr, Vender J, Howard D, Casale EJ, Murray MJ (1995) Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Anesth Analg 81:3–12Google Scholar
  11. 11.
    Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW Jr, Tescher AN, McGee WT, Prielipp RC, Susla G, Jacobi J, Nasraway SA Jr, Lumb PD, Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM) (2002) Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 30:142–156CrossRefPubMedGoogle Scholar
  12. 12.
    Taivainen T, Meakin GH, Meretoja OA, Wirtavuori K, Perkins RJ, Murphy AK, Fisher GR, Waiter MR (2000) The safety and efficacy of cisatracurium 0.15 during nitrous oxide-opioid anaesthesia in infants and children. Anaesthesia 55:1047–1051Google Scholar
  13. 13.
    Brandom BW, Woelfel SK, Ference A, Dayal B, Cook DR, Kerls S (1998) Effects of cisatracurium in children during halothane-nitrous oxide anesthesia. J Clin Anesth 10:195–199Google Scholar
  14. 14.
    Meretoja OA, Taivainen T, Wirtavuori K (1996) Cisatracurium during halothane and balanced anaesthesia in children. Paediatr Anaesth 6:373–378Google Scholar
  15. 15.
    Ruiter J de, Crawford MW (2001) Dose-response relationship and infusion requirement of cisatracurium besylate in infants and children during nitrous oxide-narcotic anesthesia. Anesthesiology 94:790–792Google Scholar
  16. 16.
    Tobias JD (1997) A prospective evaluation of the continuous infusion of cis-atracurium for neuromuscular blockade in the pediatric intensive care unit patient: efficacy and dosage requirements. Am J Ther 4:287–290Google Scholar
  17. 17.
    Odetola FO, Bhatt-Mehta V, Zahraa J, Moler FW, Custer JR (2002) Cisatracurium infusion for neuromuscular blockade in the pediatric intensive care unit: a dose-finding study. Pediatr Crit Care Med 3:250–254Google Scholar
  18. 18.
    Tobias JD (1997) Increased cis-atracurium requirements during prolonged administration to a child. Can J Anaesth 44:82–84Google Scholar
  19. 19.
    Rudis MI, Sikora CA, Angus E, Peterson E, Popovich J Jr, Hyzy R, Zarowitz BJ (1997) A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med 25:575–583Google Scholar
  20. 20.
    Newman PJ, Quinn AC, Grounds RM, Hunter JM, Boyd AH, Eastwood NB, Pollard BJ, Pearson AJ, Harper NJ, Beale RJ, Sutjarittam M, Elliot JM, Bion JF (1997) A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Crit Care Med 25:1139–1142Google Scholar
  21. 21.
    Hodges UM (1996) Vecuronium infusion requirements in paediatric patients in intensive care units: the use of acceleromyography. Br J Anaesth 76:23–28Google Scholar
  22. 22.
    Segredo V, Caldwell JE, Wright PMC, Sharma ML, Gruenke LD, Miller RD (1998) Do the pharmacokinetics of vecuronium change during prolonged administration in critically ill patients? Br J Anaesth 80:715–719Google Scholar
  23. 23.
    Kanji S, Barletta JF, Janisse JJ, Kruse JA, Devlin JW (2002) Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy. Pharmacotherapy 22:823–830Google Scholar
  24. 24.
    Harper NJ (1993) Neuromuscular blocking drugs: practical aspects of research in the intensive care unit. Intensive Care Med 19 [Suppl 5]Google Scholar
  25. 25.
    Pena O, Prestjohn S, Guzzetta CE (2000) Agreement between muscle movement and peripheral nerve stimulation in critically ill pediatric patients receiving neuromuscular blocking agents. Heart Lung 29:309–318Google Scholar
  26. 26.
    Davis NA, Rodgers JE, Gonzalez ER, Fowler AA, III (1998) Prolonged weakness after cisatracurium infusion: a case report. Crit Care Med 26:1290–1292Google Scholar
  27. 27.
    Toh KW, Deacock SJ, Fawcett WJ (1999) Severe anaphylactic reaction to cisatracurium. Anesth Analg 88:462–464Google Scholar
  28. 28.
    Clendenen SR, Harper JV, Wharen RE Jr, Guarderas JC (1997) Anaphylactic reaction after cisatracurium. Anesthesiology 87:690–692Google Scholar
  29. 29.
    Briassoulis G, Hatzis T, Mammi P, Alikatora A (2000) Persistent anaphylactic reaction after induction with thiopentone and cisatracurium. Paediatr Anaesth 10:429–434Google Scholar
  30. 30.
    Legros CB, Orliaguet GA, Mayer MN, Labbez F, Carli PA (2001) Severe anaphylactic reaction to cisatracurium in a child. Anesth Analg 92:648–649Google Scholar
  31. 31.
    Krombach J, Hunzelmann N, Koster F, Bischoff A, Hoffmann-Menzel H, Buzello W (2001) Anaphylactoid reactions after cisatracurium administration in six patients. Anesth Analg 93:1257–1259Google Scholar
  32. 32.
    Zarowitz BJ, Rudis MI, Lai K, Petitta A, Lulek M (1997) Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients. Pharmacotherapy 17:327–332Google Scholar
  33. 33.
    Splinter WM, Isaac LA (2001) The pharmacoeconomics of neuromuscular blocking drugs: a perioperative cost-minimization strategy in children. Anesth Analg 93:339–344Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Children’s Hospital BostonBostonUSA
  2. 2.Paediatric Intensive Care UnitGreat Ormond Street Hospital for Children NHS TrustLondonUK

Personalised recommendations